
Thioredoxin is a naturally occurring protein. Its existence has been known to be secreted by the body to counter stressful chemical reactions that occur with inflammation. What wasn’t known about thioredoxin is its ability to open ion channels, which allow the movement of ions. Ions are electrically charged atoms across a cell’s membrane that carries out a [...]
Continue reading 'Possible rheumatoid treatment breakthrough' »
Mayo rheumatologist researcher Kevin Moder, M.D., led an investigative team for alternate ways to reduce inflammation flare ups in patients with Lupus. The disease causes inflammation of connective tissues that can involve the skin, joints, and kidneys. The cause is unknown. The researchers evaluated mycophenolate mofetil (MMF), an immunosuppressive drug used in organ transplant cases. [...]
Continue reading 'Lupus flares reduced with immunosuppressive drug' »
A new report funded by the Agency for Healthcare Research and Quality (AHRQ), compares the benefits and harms of 3 classes of medications: Synthetic disease-modifying antirheumatic drugs (DMARDs), which includes hydroxychloroquine, leflunomide, methotrexate, and sulfasalzine. Biologic DMARDs, which inclues abatacept, adalimumab, anakinra, etanercept, infliximab, and rituximab. And corticosteroids, including drugs such as predinsone. The report [...]
Continue reading 'Rheumatoid arthritis medications most effective when combined' »
Researchers seek to identify the genes that make us susceptible to disease and illness. In two independent research projects, that searched the entire human genome for variants that increase risk of rheumatoid arthritis (RA), had remarkably similar results. The research was conducted at the Broad Institute of Harvard, in association with, Brigham and Woman’s Hospital in the [...]
Continue reading 'Two separate rheumatoid arthritis research groups have similar results' »
Since the early 1900s gold salts have been used to ease the pain and swelling of rheumatoid arthritis and other inflammatory diseases. Scientists never understood why gold worked in the treatment for arthritis and recently has been replaced by faster acting methotrexate. Now gold treatment is considered a last resort. Gold treatment take months to [...]
Continue reading 'Gold paves way for safer rheumatoid arthritis treatment' »
Ankylosing spondylitis (AS) is an inflammatory arthritis disease that strikes patients in their teens, 20s, or 30s. It can cause a complete fusion of the spine, leaving patients unable to straighten and bend. For the past 30 years the only screening test for AS was the gene HLA-B27, then only 40% of the time AS cases [...]
Continue reading '2 arthritis related genes discovered' »
At some point, medical research often involves laboratory animals. Researchers at the University of Missouri-Columbia’s Comparative Orthopedic Laboratory have found a way to minimize the use of laboratory animals when it comes to arthritis research. The Mizzou researchers have developed an in vitro model using small sections of joint capsule and cartilage that are typically [...]
Continue reading 'Arthritis research without the use of laboratory animals' »
An estimated 2.1 million Americans are afflicted with rheumatoid arthritis (RA), a chronic and debilitating inflammatory disease of the joints. American and Swedish researchers used blood samples of rheumatoid arthritis patients, along with blood samples from healthy patients, to compare DNA in search of small differences in the genetic code. Independently, both groups were led [...]
Continue reading 'Swedish & American research groups independently find new rheumatoid arthritis gene' »
Rheumatoid Arthritis (RA) and Lupus have long been suspected to have a common genetic component. Narrowing the field of possibilities to just one likely candidate has taken researchers years to accomplish. The suspected gene is STAT4, but it is too early to tell what impact it will have in therapy for both diseases. This is [...]
Continue reading 'A gene found to be common among Rheumatoid Arthritis and Lupus patients' »
Novartis is in the process of recruiting subjects for clinical trials for the drug Lumiracoxib. The clinical trials are to compare the effects of Lumiracoxib, ibuprofen, and placebo on a 24-hour blood pressure profile and on urinary excretions (of eicosanoids in controlled hypertensive) in patients who have osteoarthritis. Meanwhile, Australia’s equivalent of the FDA, the Therapeutic [...]
Continue reading 'Australia’s equivalent of FDA (TGA) bans Novartis’ Lumiracoxib' »